Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea

Journal of Korean Medical Science

Volumn 25, Issue 1, 2010, Pages 9-15

  Lee, Dae Hyoung ^a   Chung, Nak Gyun ^b   Cho, Bin ^b   Kim, Hack Ki ^b   Kang, Hyoung Jin ^c   Shin, Hee Young ^c   Ahn, Hyo Seop ^c   Yoo, Keon Hee ^d   Sung, Ki Woong ^d   Koo, Hong Hoe ^d   Kook, Hoon ^e   Hwang, Tai Ju ^e   Im, Ho Joon ^f   Seo, Jong Jin ^f   Park, Hyeon Jin ^g  

^a Hallym University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

Author keywords

Acute; Childhood; Enocitabine; Leukemia; Myeloid

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DRUG DERIVATIVE; ENOCITABINE; IDARUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CYTOGENETICS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; MALE; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SOUTH KOREA; SURVIVAL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTARABINE; CYTOGENETICS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THIOGUANINE; YOUNG ADULT;

EID: 77949319116     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.1.9     Document Type: Article

References (25)

1. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005; 19: 2025-9.
2. Smith FO, Alonzo TA, Gerbing RB, Woods WG; Arceci RJ for the Children's Cancer Group. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054-62.
3. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-8.
4. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Zeller B, Gustafsson G; Nordic Society of Pediatric Hematology and Oncology (NOPHO); AML Study Group. Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials. Leukemia 2005; 19: 2090-100.
5. Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HJ; Pediatric Oncology Group. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19: 2101-16.
6. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Ju_rgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-42.
7. Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 2002; 41: 705-18.
8. Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi JI, Ishida T, Kobayashi H. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res 1977; 37: 2481-6.
9. Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi J, Ishida T, Kobayashi H. Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine. Cancer Res 1976; 36: 2726-32.
10. Nara N, Tohda S, Suzuki T, Nagata K, Yamashita Y, Imai Y, Maruyama Y, Tomiyama J. Effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on blast progenitors of acute myeloblastic leukemia. Cancer Res 1990; 50: 7587-92.
11. Ohno R, Kato Y, Nagura E, Murase T, Okumura M, Yamada H, Ogura M, Minami S, Suzuki H, Morishima Y, Yokomaku S, Ezaki K, Kodera Y, Kawashima K, Saito H, Yamada K. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. J Clin Oncol 1986; 4: 1740-7.
12. Nagura E, Kimura K, Yamada K, Ohta K, Maekawa T, Takaku F, Uchino H, Masaoka T, Amaki I, Kawashima K, Kariyone S, Toyama K, Ichimaru M, Nomura T, Sakai Y, Takatsuki K, Hamajima N. Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia. Cancer Chemother Pharmacol 1994; 34: 23-9.
13. Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, Kim HJ, Kim HS, Song HS, Park JW, Ahn HS, Chung TJ, Cho KS, Lee KS, Choi YM. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study. Semin Hematol 1996; 33 (4 Suppl 3): 24-9.
14. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996; 14: 204-13.
15. Takashima Y. Clinical use of intermediate to high dose of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in children with acute leukemia. J Clin Pharmacol 1988; 28: 356-62.
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-8.
17. Kimura K, Ohno R, Amaki I, Hattori K, Hirota Y, Hoshino A, Ichimaru M, Ito M, Kimura I, Maekawa T, Masaoka T, Nakamura T, Ogawa M, Oguro M, Ohta K, Osamura S, Shimoyama M, Takaku F, Uzuka Y, Yamada K. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-beta-D-arabinofuranosylcytosine. Cancer 1985; 56: 1913-7.
18. Miyawaki S, Kobayashi T, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Omoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Ueda T, Tomonaga M, Ohno R. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group. Int J Hematol 1999; 70: 56-7.
19. Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, Johno I, Akiyama Y. Pharmacokinetics of N4-behenoyl-1-beta-Darabinofuranosylcytosine in patients with acute leukemia. Cancer Res 1983; 43: 3412-6.
20. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, Camitta B, Weinstein HJ. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428-34.
21. Alonzo TA, Wells RJ, Woods WG, Lange B, Gerbing RB, Buxton AB, Neudorf S, Sanders J, Smith FO, Feig SA. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia 2005; 19: 965-70.
22. Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, Sanders JE, Smith FO 3rd, Wilmot F, McCarthy PL Jr, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidencebased review. Biol Blood Marrow Transplant 2007; 13: 1-25.
23. Marcucci G, Mroózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705-17.
24. Narimatsu H, Yokozawa T, Iida H, Tsuzuki M, Hayakawa M, Takeo T, Iino M, Ichihashi T, Kato C, Sawamoto A, Sao H, Yanada M, Emi N, Kiyoi H, Yamaguchi T, Naoe T, Suzuki R, Sugiura I. Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan. Leukemia 2008; 22: 428-32.
25. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108: 3654-61.